[DOI] [PMC free article] [PubMed] [Google Scholar] 103.Sitagliptin: Summary of Product Characteristics
The key findings were: Tirzepatide met the primary goal of cardiovascular non-inferiority , confirming it is at least as safe for the heart as dulaglutide It did not quite meet statistical superiority over dulaglutide for MACE, although results trended in favour of tirzepatide Tirzepatide produced significantly greater reductions in HbA1c and body weight than dulaglutide Importantly, because SURPASS-CVOT used an active comparator with established cardiovascular benefit rather than a placebo, demonstrating superiority was inherently more difficult than in earlier placebo-controlled GLP-1 outcome trials
This is how it should be
HB: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Validation, Visualization, Writing original draft, Writing review & editing
See our guide on how long reconstituted peptides last to plan your supply for extended protocols
While more research is needed, this case report suggests that glutathione may help reduce symptoms, improving quality of life in people with this disease
